Palatin Technologies is a biopharmaceutical company based in New Jersey. They develop targeted therapeutics for various diseases, with a focus on women's health and inflammatory bowel diseases. Their lead product, Vyleesi, is used to treat hypoactive sexual desire disorder in premenopausal women. They are also working on other products, including PL8177 for inflammatory bowel diseases and PL9643 for ocular indications. They have entered Phase 2 clinical trials for PL3994 and L8177. The company was founded in 1986.